# Huihe Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huihe-medical

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Total disclosed funding: $15M
- Latest round: Series D (Dec 27, 2025)
- Investors on record: 13

## About

Established in 2019 and based in Shanghai, China, Shanghai Huihe Medical Technology Co., Ltd., trading as Huihe Medical operates a medical equipment company that engages research and development of interventional medical instruments for structural heart disease. The company's founder, Lin Lin, was a cardiologist. Huihe Medical has applied for more than 200 patents, including more than 120 invention patents, among which 20 invention patents have been authorized. In December 2025, Huihe Medical raised Series D funding from new investor Tppoly Capital and returning investor Sherpa Healthcare Partners.
The company works with hospitals and healthcare providers to deliver cardiovascular intervention devices, diagnostic tools, and related services. Huihe Medical emphasizes precision engineering and compliance with clinical standards to support complex cardiovascular procedures. 
The company’s revenue is generated by sales of cardiovascular medical devices and related services to hospitals and healthcare institutions.

## Funding rounds

- Series D, Dec 27, 2025 — Sherpa Healthcare Partners, Tppoly Capital
- Series C, Dec 7, 2022 — IDG Capital, Haitong-Fortis Private Equity Fund Management, Shanghai Sci-Tech Innovation Center Capital, Sherpa Healthcare Partners, Shanghai Growth Investment, Songjiang SDIC
- Series C, Nov 23, 2022 — GTJA Innovation Investment
- Series B, Sep 15, 2021 — Sherpa Healthcare Partners
- Series B, Jul 2, 2021 — IDG Capital, Legend Star, Shanghai Sci-Tech Innovation Center Capital, Suzhou Xiangtang Guarantee, Shanghai Growth Investment
- Series A, Nov 12, 2020, $15M — Oriza Holdings, SDIC Unity Capital, BioTrack Capital, Shanghai Growth Investment

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- SDIC Unity Capital (https://capitalatlas.ai/funds/sdic-unity-capital) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series A, Series B, Series C
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B, Series C
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series B
- Shanghai Sci-Tech Innovation Center Capital (https://capitalatlas.ai/funds/shanghai-sci-tech-innovation-center-capital) — Series B, Series C
- Suzhou Xiangtang Guarantee — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B, Series C, Series D
- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Series C
- Haitong-Fortis Private Equity Fund Management (https://capitalatlas.ai/funds/haitong-fortis-private-equity-fund-management) — Series C
- Songjiang SDIC — Series C
- Tppoly Capital (https://capitalatlas.ai/funds/tppoly-capital) — Series D